Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07447024

Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
45 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate the therapeutic efficacy of exercise rehabilitation program on upper limb range and forward head posture post unilateral radical mastectomy.

Detailed description

Upper cross syndrome (forward head posture and rounded shoulder) is a major problem facing physical therapist, which causes an increase in pain, limitation of quality of life and delayed rehabilitation process. The lack in knowledge and information in the published studies about effects of exercise program in forward head posture and rounded shoulder in female's management post unilateral mastectomy. This study will be carried out to investigate the effectiveness exercise program in improving the range of motion in shoulder and forward head posture in females post unilateral mastectomy.

Conditions

Interventions

TypeNameDescription
OTHERSelected exercise programPatients who have upper cross syndrome post unilateral modified radical mastectomy and who will receive exercise program (strengthening, active range of motion exercise, and strengthening exercises including prone scapular stabilization, shoulders shrug McKenzie exercise for neck, repeated shoulder horizontal adduction, repeated shoulder flexion, repeated shoulder extension, neck flexion McKenzie exercises) and routine medical treatment. Patients will receive 3 sessions per week for 12weeks, time of session is 45 minutes.
DRUGRoutine medical therapyFor pain relief: Acetaminophen: 2 pills two times per day. Ibuprofen 400 mg: 1 pill two times per day. Hormonal therapy: Tamoxifen 20 mg: once daily. Silicone gel creams (Biocorneum): 3 times per day. These medications will be given for all patients throughout the treatment period (12 weeks).

Timeline

Start date
2026-03-02
Primary completion
2026-06-07
Completion
2026-06-15
First posted
2026-03-03
Last updated
2026-03-03

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07447024. Inclusion in this directory is not an endorsement.